Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Fibrosis, and Cardiovascular Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for THBS1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | THBS1 Recombinant Protein HEK293 expressed, High purity (>95%), Endotoxin Controlled, Sequence Verified, Native Glycosylation. |
View THBS1 Products |
| Gene Delivery | THBS1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View THBS1 Products |
| Benchmark Ab | Anti-THBS1 Recombinant Antibody Recombinant positive control for assay validation. |
View THBS1 Products |
| Validator | THBS1 siRNA Set For target knockdown verification. |
View THBS1 Products |
| Related Target A | CD47 Primary receptor for THBS1; mediates immunosuppressive and cardiovascular signaling. |
View CD47 Products |
| Related Target B | CD36 Co-receptor for THBS1; mediates anti-angiogenic and metabolic signaling pathways. |
View CD36 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preservation of complex homotrimeric structure | HEK293 mammalian expression system ensures correct folding and post-translational glycosylation. |
| Cross-species ortholog evaluation (Human/Mouse) | Sequence verified human, mouse, and cynomolgus orthologs available with >95% purity. |
| Receptor binding specificity (CD47 vs CD36) | High-purity receptor proteins and benchmark antibodies available for competitive ELISA and SPR assays. |
| Lack of reliable positive controls | Sequence-verified clinical-grade benchmark antibodies included in the catalog. |
| Off-target assay noise | Sequence verified siRNA sets included to confirm knockdown specificity in cell-based assays. |
Live THBS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Thrombospondin 1 (THBS1) is experiencing a resurgence. Historically known as a major regulator of angiogenesis, modern drug discovery focuses on THBS1 as a critical ligand for CD47, where it limits nitric oxide (NO) signaling and drives immunosuppressive pathways in the tumor microenvironment. Blocking the THBS1-CD47 axis is a major therapeutic trend to restore immune surveillance and improve tissue perfusion.
As first-generation CD47-targeting therapies face clinical challenges such as hemagglutination, targeting THBS1 directly—or blocking its specific interaction with CD47—emerges as a safer, highly localized alternative. Additionally, THBS1 plays a pivotal role in TGF-beta activation, making it a high-value target for pulmonary fibrosis and cardiovascular diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Arch Oncology, Boehringer Ingelheim | Solid Tumors, Fibrosis | Epitope mapping & ligand-blocking assays (Need high-purity THBS1 and CD47 proteins) |
| Peptide Mimetics | Academic institutions, Biotech startups | Ischemic diseases, Cardiovascular | Receptor binding affinity assays (Need native homotrimeric THBS1) |
| Small Molecules | Preclinical stage biotechs | Pulmonary Hypertension, Cancer | High-throughput screening assays (Need sequence-verified target proteins and stable cell lines) |